Figure 1.
Figure 1. Study design of ongoing phase 3 IFM/DFCI trial (ClinicalTrials.gov identifier NCT01208662). LEN indicates lenalidomide; and MEL 200, 200 mg/m2 melphalan. *MEL 200/ASCT given at relapse.

Study design of ongoing phase 3 IFM/DFCI trial (ClinicalTrials.gov identifier NCT01208662). LEN indicates lenalidomide; and MEL 200, 200 mg/m2 melphalan. *MEL 200/ASCT given at relapse.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal